These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 35677056)

  • 1. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
    Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
    Front Immunol; 2022; 13():907673. PubMed ID: 35677056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
    Cassady K; Martin PJ; Zeng D
    Front Immunol; 2018; 9():3061. PubMed ID: 30622541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
    Li Q; Wang X; Song Q; Yang S; Wu X; Yang D; Marié IJ; Qin H; Zheng M; Nasri U; Kong X; Wang B; Lizhar E; Cassady K; Tompkins J; Levy D; Martin PJ; Zhang X; Zeng D
    J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 serves as a double agent in separating GVL from GVHD.
    Brennan TV; Yang Y
    J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of T-cell-suppressive PD-L1
    Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
    Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
    J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway.
    Sofi MH; Tian L; Schutt S; Khan I; Choi HJ; Wu Y; Bastian D; Ticer T; Kassir MF; Atilgan FC; Kim J; Sui X; Zivkovic A; Mehrotra S; O'Bryan JP; Stark H; Martin PJ; Ogretmen B; Yu XZ
    Leukemia; 2022 Jul; 36(7):1907-1915. PubMed ID: 35513703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
    Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
    Front Immunol; 2020; 11():593863. PubMed ID: 33324410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icariin protects against acute graft-versus-host disease while preserving graft-versus-leukemia activity after allogeneic hematopoietic stem cell transplantation.
    Su L; Wei ZF; Pi CC; Qin TX; Song F; Zhang YW; Gao SJ
    Phytomedicine; 2024 Sep; 132():155901. PubMed ID: 39067193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Separation of GVL from GVHD -location, location, location.
    Teshima T; Hashimoto D
    Front Immunol; 2023; 14():1296663. PubMed ID: 38116007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
    Chang YJ; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of regulatory T cells on the graft-versus-leukemia effect.
    Pacini CP; Soares MVD; Lacerda JF
    Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.
    Asakura S; Hashimoto D; Takashima S; Sugiyama H; Maeda Y; Akashi K; Tanimoto M; Teshima T
    J Clin Invest; 2010 Jul; 120(7):2370-8. PubMed ID: 20530875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
    Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
    Front Immunol; 2019; 10():295. PubMed ID: 30891031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation.
    Tian L; Ogretmen B; Chung BY; Yu XZ
    Front Immunol; 2022; 13():904823. PubMed ID: 36052066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.